Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced its participation in the Sidoti Micro-Cap Virtual Investor Conference scheduled for May 20-21, 2026. The company will present at 3:15 p.m. ET on May 21, 2026, and will host virtual one-on-one meetings with investors throughout the conference.
This event provides an opportunity for Oragenics to showcase its proprietary intranasal delivery technology, which is being developed to treat a range of neurological conditions. The company's lead candidate, ONP-002, is being positioned as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow.
The intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. This platform could offer a non-invasive method to deliver therapeutics directly to the brain, addressing significant unmet medical needs in neurological care.
Investors and industry observers will be watching for updates on the company's clinical trial progress and strategic partnerships. The Sidoti conference is a key venue for micro-cap companies to connect with potential investors, and Oragenics' participation underscores its commitment to advancing its pipeline.
For more information about Oragenics, visit oragenics.com. The latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN.
The Sidoti Micro-Cap Virtual Investor Conference is a platform for emerging growth companies to present their investment theses. Oragenics' presentation and meetings could provide insights into the company's strategy and milestones. The conference will be held virtually, allowing broad access for investors.
Oragenics is a clinical-stage biotechnology company developing brain-targeted therapeutics through its intranasal delivery technology. The company's focus on concussion and mild traumatic brain injury addresses a condition that affects millions annually, with limited treatment options. Successful development of ONP-002 could have a significant impact on patient outcomes and the neurological therapeutics market.
The announcement of the conference participation comes as Oragenics progresses its clinical plans. The company's ability to secure funding, partnerships, and regulatory approvals will be critical factors in its success. The Sidoti conference offers a venue to communicate these developments to the investment community.
